📊 ZIVOW Key Takeaways
Is Zivo Bioscience, Inc. (ZIVOW) a Good Investment?
Zivo Bioscience is technically insolvent with negative $3.3M equity and faces an acute liquidity crisis with only $57.2K cash against $2.2M annual operating losses. The company generates $119K revenue while burning $6.9M operationally, indicating a non-viable business model with critical going concern risk requiring immediate capital restructuring.
Zivo Bioscience, Inc. Key Strengths (ZIVOW)
- Gross margin of 32.9% demonstrates pricing power on products actually sold
- Operates in biological products sector with inherent long-term growth potential
- Recent insider activity (7 Form 4 filings) suggests management engagement
ZIVOW Stock Risks: Zivo Bioscience, Inc. Investment Risks
- Negative stockholders equity of -$3.3M indicates balance sheet insolvency
- Critical liquidity crisis with current ratio 0.08x and estimated 2-3 week cash runway
- Operating losses $6.9M versus revenue $119K creates immediate going concern threat
- Negative operating cash flow of -$2.2M annually with minimal revenue growth
- No viable path to profitability or break-even without transformational revenue growth or cost elimination
Key Metrics to Watch
- Cash position and burn rate runway to complete depletion
- Quarterly operating cash flow and cash consumption rate
- Revenue growth rate and ability to materially increase sales
- Debt restructuring, refinancing, or capital raise announcements
- Going concern assessment and audit opinion in next SEC filings
Zivo Bioscience, Inc. (ZIVOW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ZIVOW Profit Margin, ROE & Profitability Analysis
ZIVOW vs Healthcare Sector: How Zivo Bioscience, Inc. Compares
How Zivo Bioscience, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zivo Bioscience, Inc. Stock Overvalued? ZIVOW Valuation Analysis 2026
Based on fundamental analysis, Zivo Bioscience, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zivo Bioscience, Inc. Balance Sheet: ZIVOW Debt, Cash & Liquidity
ZIVOW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zivo Bioscience, Inc.'s revenue has grown significantly by 469% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.60 indicates the company is currently unprofitable.
ZIVOW Revenue Growth, EPS Growth & YoY Performance
ZIVOW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $31.5K | -$1.0M | $-0.27 |
| Q2 2025 | N/A | -$1.6M | $-0.43 |
| Q1 2025 | N/A | -$1.3M | $-0.47 |
| Q3 2024 | $11.8K | -$1.8M | N/A |
| Q2 2024 | N/A | -$2.1M | N/A |
| Q1 2024 | N/A | -$1.3M | N/A |
| Q3 2023 | N/A | -$1.8M | N/A |
| Q2 2023 | N/A | -$2.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zivo Bioscience, Inc. Dividends, Buybacks & Capital Allocation
ZIVOW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zivo Bioscience, Inc. (CIK: 0001101026)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZIVOW
What is the AI rating for ZIVOW?
Zivo Bioscience, Inc. (ZIVOW) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZIVOW's key strengths?
Claude: Gross margin of 32.9% demonstrates pricing power on products actually sold. Operates in biological products sector with inherent long-term growth potential.
What are the risks of investing in ZIVOW?
Claude: Negative stockholders equity of -$3.3M indicates balance sheet insolvency. Critical liquidity crisis with current ratio 0.08x and estimated 2-3 week cash runway.
What is ZIVOW's revenue and growth?
Zivo Bioscience, Inc. reported revenue of $119.0K.
Does ZIVOW pay dividends?
Zivo Bioscience, Inc. does not currently pay dividends.
Where can I find ZIVOW SEC filings?
Official SEC filings for Zivo Bioscience, Inc. (CIK: 0001101026) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZIVOW's EPS?
Zivo Bioscience, Inc. has a diluted EPS of $-1.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZIVOW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Zivo Bioscience, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZIVOW stock overvalued or undervalued?
Valuation metrics for ZIVOW: ROE of N/A (sector avg: 15%), net margin of -5,784.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ZIVOW's AI grade for 2026?
Our dual AI analysis gives Zivo Bioscience, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZIVOW's free cash flow?
Zivo Bioscience, Inc.'s operating cash flow is $-2.2M, with capital expenditures of $0.0. FCF margin is -1,825.8%.
How does ZIVOW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,784.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.08 (avg: 2).